Treatment regimens for PCNSL
| Study (number of patients) . | Regimen . | Response rate . | Median PFS . | Median OS . |
|---|---|---|---|---|
| WBRT | ||||
| Nelson et al, 199261 (N = 41) | WBRT 40 Gy + 20 Gy boost | 100% | MA | 12.2 |
| MTX monotherapy | ||||
| Batchelor et al, 200372 (N = 23) | MTX 8 g/m2 | 74% | 12.8 | >23 |
| Herrlinger et al, 200578 (N = 37) | MTX 8 g/m2 | 35% | 10 | 25 |
| Combined-modality therapy | ||||
| Ferreri et al, 200977 (N = 40) | MTX 3.5 g/m2 + WBRT (36-45 Gy) | 41% | 4 | 10 |
| Ferreri et al, 200977 (N = 39) | MTX 3.5 g/m2 + HD-AC + WBRT (36-45 Gy) | 69% | 8 | 32 |
| DeAngelis et al, 200274 (N = 102) | MPV + IT MTX + WBRT (45 Gy) + HD-AC | 94% | 24 | 37 |
| Shah et al, 2007110 (N = 30) | R-MPV + HD-AC + WBRT (23 Gy) | 93% | >37 | 40 |
| Intensive chemotherapy | ||||
| Illerhaus et al, 20086 (N = 13) | MTX 8 g/m2 + HD-AC/TT+ BCNU/TT (ASCT) | 85% | NR | NR |
| Rubenstein et al, 20135 (N = 44) | MT-R + EA | 77% | 52 | NR |
| Study (number of patients) . | Regimen . | Response rate . | Median PFS . | Median OS . |
|---|---|---|---|---|
| WBRT | ||||
| Nelson et al, 199261 (N = 41) | WBRT 40 Gy + 20 Gy boost | 100% | MA | 12.2 |
| MTX monotherapy | ||||
| Batchelor et al, 200372 (N = 23) | MTX 8 g/m2 | 74% | 12.8 | >23 |
| Herrlinger et al, 200578 (N = 37) | MTX 8 g/m2 | 35% | 10 | 25 |
| Combined-modality therapy | ||||
| Ferreri et al, 200977 (N = 40) | MTX 3.5 g/m2 + WBRT (36-45 Gy) | 41% | 4 | 10 |
| Ferreri et al, 200977 (N = 39) | MTX 3.5 g/m2 + HD-AC + WBRT (36-45 Gy) | 69% | 8 | 32 |
| DeAngelis et al, 200274 (N = 102) | MPV + IT MTX + WBRT (45 Gy) + HD-AC | 94% | 24 | 37 |
| Shah et al, 2007110 (N = 30) | R-MPV + HD-AC + WBRT (23 Gy) | 93% | >37 | 40 |
| Intensive chemotherapy | ||||
| Illerhaus et al, 20086 (N = 13) | MTX 8 g/m2 + HD-AC/TT+ BCNU/TT (ASCT) | 85% | NR | NR |
| Rubenstein et al, 20135 (N = 44) | MT-R + EA | 77% | 52 | NR |
Note that for Ferreri et al (2009), the median failure-free survival is represented in the table.
ASCT, autologous stem cell transplant; EA, infusional etoposide plus high-dose cytarabine; HD-AC, high-dose cytarabine; IT, intrathecal; MPV, methotrexate plus procarbazine and vincristine; MT-R, methotrexate plus temozolomide and rituximab; MTX, methotrexate; TT, thiotepa; WBRT, whole-brain radiotherapy.